GLP-1 receptor agonists (drugs like semaglutide and tirzepatide) produce substantial weight loss, but a portion of that loss is lean mass, not just fat. Estimates from clinical trials suggest lean mass accounts for roughly 25–40% of total weight lost (Wilding 2021). This has prompted researchers to explore adjunctive agents that might shift the ratio toward fat loss while sparing muscle. Among the candidates are growth hormone-releasing peptides (GHRPs), which stimulate endogenous growth hormone (GH) secretion and, downstream, insulin-like growth factor-1 (IGF-1). Two GHRPs often compared in this context are hexarelin (a synthetic hexapeptide) and tesamorelin (a 44-amino acid analog of growth hormone-releasing hormone, or GHRH). Both increase GH output, but they differ in receptor selectivity, half-life, and the downstream anabolic signals they generate. This article examines what the research says about their potential to preserve muscle during GLP-1-assisted weight loss, where the evidence stands, and what remains unknown.
How GHRPs Signal Muscle Preservation
Growth hormone-releasing peptides act on the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, triggering pulsatile GH release. Hexarelin is a potent synthetic agonist of this receptor, with additional affinity for the CD36 receptor in cardiac and vascular tissue (Muccioli 2007). Tesamorelin, by contrast, is a GHRH analog that binds the GHRH receptor to stimulate GH secretion more directly, without activating the ghrelin receptor. Both raise serum IGF-1, which mediates many of the anabolic effects on skeletal muscle. IGF-1 promotes protein synthesis and inhibits proteolysis, creating a net anabolic environment (Velloso 2008). In theory, maintaining higher IGF-1 during caloric restriction could counteract the catabolic drive that accompanies GLP-1-induced weight loss. IGF-1 LR3, a long-acting analog, has been studied for muscle recovery and may share mechanistic overlap with GHRP-induced IGF-1 elevation. However, the magnitude and tissue specificity of the IGF-1 response differ between hexarelin and tesamorelin, which may influence outcomes.
Hexarelin: Potent GH Pulse but Limited Lean Mass Data
Hexarelin produces a rapid, high-amplitude GH pulse that peaks within 30 minutes and returns to baseline within a few hours (Arvat 2001). This pulsatility is thought to more closely mimic physiological GH secretion than continuous infusion. In animal models, hexarelin has shown protective effects on cardiac muscle and bone, but direct evidence for skeletal muscle preservation during weight loss is sparse. A small study in healthy older adults found that hexarelin increased lean body mass over 16 weeks, though the effect was modest (Broglio 2004). Most human data come from short-term metabolic studies or investigations of cardiac function, not muscle-specific outcomes. Comparisons of hexarelin and GLP-1 drugs for bone density highlight hexarelin's potential to offset bone loss, but muscle endpoints remain largely unexplored. The lack of randomized trials combining hexarelin with GLP-1 agonists means any muscle-sparing claim is extrapolated from its GH-releasing properties and limited body composition data.
Tesamorelin: Approved for Visceral Fat, Not Muscle
Tesamorelin is FDA-approved for reducing excess visceral adipose tissue in HIV-associated lipodystrophy. Its effects on lean mass have been secondary endpoints in these trials. A meta-analysis of four randomized controlled trials found that tesamorelin increased lean body mass by approximately 1.3 kg over 26 weeks, while reducing visceral fat (Falutz 2010). The increase in lean mass was statistically significant but modest, and it is unclear whether this represents true muscle hypertrophy or simply fluid retention and connective tissue changes. Tesamorelin's longer half-life (roughly 30–40 minutes) leads to a more sustained GH elevation than hexarelin, which may influence the IGF-1 response. Some investigators have proposed combining tesamorelin with GLP-1 agonists to mitigate lean mass loss, but no published studies have tested this hypothesis directly. The existing data come from populations with baseline GH deficiency or altered fat distribution, not from otherwise healthy individuals undergoing pharmacologic weight loss.
Comparative Research: Gaps and Indirect Evidence
No head-to-head trial has compared hexarelin and tesamorelin for muscle preservation during GLP-1-assisted weight loss. The closest indirect evidence comes from studies of GH secretagogues in catabolic states. A review of GHRPs in critical illness noted that hexarelin and other ghrelin mimetics can attenuate protein breakdown, but the effect size is small and inconsistent (Singer 2013). Tesamorelin's lean mass data from HIV studies suggest a possible anabolic signal, but the catabolic drivers in HIV lipodystrophy differ from those in GLP-1-induced weight loss. Research on hexarelin and semaglutide for bone density in athletes illustrates the broader interest in pairing GHRPs with GLP-1 drugs, yet muscle endpoints are missing. Another gap is the interaction between GHRPs and the GLP-1 pathway itself. GLP-1 agonists slow gastric emptying and may alter absorption of subcutaneously administered peptides, though this has not been systematically studied for hexarelin or tesamorelin.
Safety and Receptor Considerations
Both hexarelin and tesamorelin carry theoretical risks that could limit their use in weight-loss protocols. Hexarelin's activation of the CD36 receptor has been linked to increased atherosclerotic plaque development in animal models, raising cardiovascular concerns (Demers 2004). Tesamorelin's GHRH receptor agon
Peptides referenced here are research chemicals. Their use outside of approved clinical settings is not endorsed.